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 Solid organ transplant patients are at an increased risk of developing cutaneous 
malignancies owing to long-lasting immunosuppression. The strongest increase in 
incidence (35-fold) has been reported for cutaneous squamous cell carcinoma[1]. 
Basal cell carcinoma (BCC) may occur even more frequently, especially during the 
first years after transplantation[2].  The hedgehog-inhibitor vismodegib has been 
safely used for the treatment of locally advanced or metastatic BCC in 
immunocompetent patients since 2012 [3]. The experience regarding efficacy and 
safety of vismodegib use in organ transplant patients is limited.[4, 5]  
We report a 72-year-old male caucasian patient with a history of renal transplantation 
who had been first diagnosed with a BCC of the nose in 1993 and subsequently 
underwent numerous surgical and radiotherapeutic interventions for his recurring 
tumour. Last in May 2016, a left-sided maxillectomy and partial resection of the 
zygomatic bone with defect closure via a scapula/latissimus dorsi-graft had been 
performed, but also this extensive intervention only yielded a R1-situation with 
infiltration of the orbital floor. As the patient refused orbital exenteration and another 
course of radiotherapy was infeasible with regard to pre-treatment dose of 60 Gray, 
the responsible interdisciplinary tumour board decided to offer vismodegib treatment. 
Postoperative imaging could not delineate distinct tumour remnants, yielding an 
adjuvant treatment situation. Routinely, the patient was on 5 mg of prednisone once 
and 0.5 mg of everolimus twice daily for immunosuppression. Since a search of the 
literature did not reveal any results on the concurrent use of everolimus and 
vismodegib, we excluded potentially harmful drug interactions with the drug 
manufacturer and our pharmacological department. Thereafter, treatment was 
initiated with the standard dose of vismodegib (150 mg once daily) in June 2016.  
Initially, it was well tolerated and the first MRT-scan after 3 months revealed no signs 
of disease recurrence (Fig. 1). Regular laboratory tests (complete blood count, renal 
and liver function parameters) did not indicate any drug interactions. Subsequently, 
the patient developed increasing dysgeusia as well as alopecia of the scalp and 
eyebrows, both well-known side effects of vismodegib[6] (Fig. 2).  After another 
unchanged MRT-scan in December 2016, we offered the patient an intermittent 
dosing-schedule of vismodegib to decrease side effects and improve quality of life. 
The patient consented to a 12-weeks-on/8-weeks-off schedule, according to arm A of 
the MIKIE study [7]. As of April 2017, the patient has completed his first drug holiday 
and regained sense of taste.     
To our knowledge, we report the first case of concurrent use of vismodegib with 
mTOR-inhibitors in a transplant patient. Due to exclusion of transplant patients from 
clinical trials, data on the use of vismodegib post-transplantation are scarce. Also, 
locally advanced or metastasizing BCC may be less frequent in this patient 
population, owing to regular dermatological follow-up. Yet, local recurrence and 
invasion of BCC can occur despite continuous surveillance, eventually resulting in an 
indication for systemic therapy. Due to the aggressive course that BCC can take in 
immunosuppressed patients, adjuvant vismodegib treatment in a high-risk R1- 
situation as described seems reasonable.  
Significant side effects occur in the majority of  vismodegib patients, resulting in 
treatment discontinuation in almost 30% of patients [8]. Hence, intermittent dosing 
schedules of vismodegib have been recently investigated and may especially be 
feasible in transplant patients requiring long-term treatment for recurrent invasive 
BCC [7].  
Concerning the combination of vismodegib with everolimus, a potential synergistic 
effect of mTOR- and hedgehog pathway-inhibition due to crosstalk of these pathways 
is of particular interest and has been supposed in different types of cancer [9]. Also in 
BCC, a potential role of the mTOR pathway is conceivable, as the incidence of BCC 
in transplant patients is reduced when mTOR inhibitors are used first-line for 
immunosuppression [10]. 
In conclusion, the concomitant use of everolimus and vismodegib appears to be safe 
and efficacious in our patient. Together with other reports published, this should 
encourage the inclusion of organ transplant recipients - in particular those treated 
with mTOR-inhibitors - in future clinical trials with hedgehog pathway inhibitors. 
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Figure 1: Clinical Picture 
(a) Patient at first presentation at our hospital in June 2013 with a visible recurrence 
of the basal cell carcinoma (black arrow). 
(b) Preoperative picture before left-sided maxillectomy and partial resection of the 
zygomatic bone in May 2016. 
(c) Patient after six months of vismodegib treatment without signs of disease 
recurrence in December 2016. Increasing alopecia of scalp hair and eyebrows was 
attributed to vismodegib. 
 
 
 Figure 2: Magnetic resonance tomography (MRT) imaging 
Sequential MRT scans showing diffuse postoperative oedematous changes in June 
2016, five weeks after left-sided maxillectomy and scapula/latissimus dorsi-graft 
reconstruction. Subsequent MRTs during vismodegib treatment show regression of 
the postoperative fluid retention without signs of tumour recurrence. Physiologic fatty 
degeneration of the latissimus flap can be observed (a: T1-weighted sequence, b: 
T1-weighted, fat-suppressed sequence with Gadolinium contrast media). 
